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Abstract 23 
Membrane proteins (MP) constitute 20-30 % of all proteins encoded by the genome of 24 
various organisms and perform a wide range of essential biological functions. However, despite 25 
they represent the largest class of protein drug targets, a relatively small number high-resolution 26 
3D structures have been obtained yet. Membrane protein biogenesis is more complex than that 27 
of the soluble proteins and its recombinant biosynthesis has been a major drawback, thus 28 
delaying their further structural characterization. Indeed, the major limitation in structure 29 
determination of MP is the low yield achieved in recombinant expression, usually coupled to 30 
low functionality, pinpointing the optimization target in recombinant MP research. Recently, the 31 
growing attention that have been dedicated to the upstream stage of MP bioprocesses allowed 32 
great advances, permitting the evolution of the number of MP solved structures. In this review, 33 
we analyse and discuss effective solutions and technical advances at the level of the upstream 34 
stage using prokaryotic and eukaryotic organisms foreseeing an increase in expression yields of 35 
correctly folded MP and that may facilitate the determination of their three-dimensional 36 
structure. A section on techniques used to protein quality control and further structure 37 
determination of MP is also included. Lastly, a critical assessment of major factors contributing 38 
for a good decision-making process related to the upstream stage of MP is presented. 39 
 40 
41 
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1. Recombinant membrane protein biosynthesis 42 
Membrane proteins (MP) constitute 20-30 % of all proteins encoded by the genome of 43 
various organisms (Lantez et al 2015) and perform a wide range of essential biological 44 
functions, thus representing the largest class of protein drug targets (Bernaudat et al 2011). 45 
However and despite their biological relevance, most of these targets still do not have any 46 
assigned function (Bernaudat et al 2011), as reflected by the relatively low number of MP 47 
structures recorded in Stephen White’s laboratory database 48 
(http://blanco.biomol.uci.edu/mpstruc/) - 876 unique MP structures in March 2019. Indeed, 49 
determining the structure of a MP is quite complex, mostly due to problems arising from MP 50 
low natural abundance, their toxicity when overexpressed in heterologous systems, and 51 
difficulties in purifying stable functional proteins and obtaining well-diffracting crystals (Gul et 52 
al 2014; Lantez et al 2015). To cope with MP low natural abundance that limits subsequent 53 
structural and functional studies, four different approaches have been proposed (Popot 2018), 54 
namely: 1) overexpression in vivo and in situ; 2) overexpression in vivo in inclusion bodies; 3) 55 
cell-free expression (CFE) in vitro; 4) chemical synthesis for short MP or MP fragments. Here, 56 
we will generally address the first two approaches based on the following host cells: 57 
Escherichia coli (E. coli), Pichia pastoris (P. pastoris), also known as Komagataella phaffii, 58 
mammalian cell lines. The process to obtain a recombinant protein involves the synergy of three 59 
key elements – a gene, a vector and an expression host – (Bernaudat et al 2011) and, at least at 60 
the theoretical level, is straightforward (Rosano et al 2014). In practice, many things can go 61 
wrong, and distinct problems can be found including poor growth of the host, inclusion body 62 
formation or lack of protein biological activity (Rosano et al 2014). Indeed, targeting an 63 
overexpressed MP to a membrane in such a way they can insert and achieve its native structure 64 
is far from being an easy task, once they tend to be toxic, leading to low expression yields of 65 
often misfolded and aggregated MP (Popot 2018; Rajesh et al 2011). Moreover, the high 66 
diversity of structures and physico-chemical properties displayed by MP makes unfeasible to 67 
accurately predict if a protein of interest will express well, be easy to purify, be biologically 68 
active or crystallize in any given experimental protocol (Bernaudat et al 2011). Based on the 69 
exposed, the development of improved strategies in the recombinant MP production pipeline 70 
foreseeing to increase their expression yields in a correctly folded form is crucial in MP 71 
research. The evaluation of purified protein quality is crucial in any protein production process 72 
and should be accurately performed to avoid irreproducible and misleading observations in the 73 
subsequent studies (Raynal et al 2014). After production, MP need to be efficiently solubilized 74 
(recently reviewed by Hardy et al 2018 and Popot 2018) and purified (Pandey et al 2016), from 75 
which their quality in terms of purity, homogeneity, activity and structural conformity should be 76 
assessed (Oliveira and Domingues et al 2018; Raynal et al 2014). In this review, generic 77 
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guidelines and host characteristics aiming an accurate choice of the host expression system that 78 
better suits particular needs will be initially overviewed in this review, and then we discuss 79 
important advances reported at the level of the upstream stage of recombinant MP production 80 
processes using E. coli, P. pastoris and mammalian cell lines, representative of major 81 
expression systems used for protein expression. Subsequently, general techniques to perform the 82 
quality control of the target protein are presented and at the end, insights and directions for a 83 
successful MP production pipeline are shown. 84 
 85 
1.1. Economics vs complexity: guidelines to choose the right host 86 
The most common systems for MP overexpression are microbial (bacteria or yeasts) or 87 
higher eukaryotes (insect or mammalian cells) [reviewed in (Bernadaut et al 2011; Fernández 88 
and Vega 2016; He et al 2014; Midgett et al 2007; Wagner et al 2006)]. There is no such a 89 
perfect host that suits all MP expression projects once they all have advantages and limitations, 90 
as highlighted in Table 1. Moreover, the reasons why some MP are overexpressed but others are 91 
expressed at low levels are not fully known, although it can be related to how difficult is to fold 92 
MP into a functional state (Andréll and Tate 2013).  93 
In terms of increasing complexity, the expression systems can be grouped as follows: 94 
bacteria < yeasts < insect cells < mammalian cell lines. With an increasing complexity, there is 95 
generally an increase in the ability of the host cell to perform native post-translational 96 
modifications (PTM). As such, heavily glycosylated proteins are expected to be produced in a 97 
more native and folded form from mammalian cell lines, and those obtained from yeasts may 98 
not present the native glycosylation profile. On the other hand, simpler hosts such as bacteria 99 
allow high productivities, and combine the speed with easiness of operation at a lower cost. 100 
Requirements in terms of specific PTM or a near-native-like environment for some 101 
mammalian MP are usually the factors dictating the choice of mammalian cell lines, which 102 
usually makes use of human embryo kidney (HEK) and Chinese hamster ovary (CHO) cell lines 103 
and both cell lines can be applied in stable and transient transfections (He et al 2014; Lyons et al 104 
2016). The process of recombinant protein production by transient expression involves the 105 
generation of plasmid, transfection in log phase, optional feeds from 24h onwards and then 106 
harvest from 48h to 14 days, depending on the target protein, cell line and culture conditions 107 
applied (McKenzie et al 2018). Contrasting with transient expression, stably transfected cell 108 
lines takes more time (months) and usually requires the stable integration of the recombinant 109 
DNA into the host cell genome. Since the expression vector has a gene conferring resistance to 110 
an antibiotic, stable integrants can be identified by antibiotic selection; moreover, the integration 111 
of the gene into the host genome may be random or the host cell can be engineered to contain a 112 
specific sequence recognized by a recombinase that allows targeted integration. Selection of 113 
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clonal cells is additionally required to identify highly expressing cell lines that are stable under 114 
prolonged culture (Andréll and Tate 2013). Transient transfection is quick but after scaling-up, 115 
batch-to-batch variability in the amount of protein expressed is often observed; on the other 116 
hand, although stable gene expression is initially slower and more technically challenging once 117 
a clonal cell line is generated, long-term overexpression can be much more consistent, and the 118 
purification of large quantities of supercoiled plasmid DNA for transient-expression is not 119 
required (Chaudhary et al 2012; Andréll and Tate 2013). Despite the slow growth rate and 120 
usually higher cost, the number of MP structures generated based on such systems has 121 
considerably increased, being foreseeable that with the increasing use of cryo electron 122 
microscopy for structure determination wherein lesser amount of sample is required (e.g. in 123 
comparison with crystallographic studies), mammalian systems will be more frequently used 124 
(Lyons et al 2016).  125 
Other interesting features to be considered when selecting a host: 1) native intracellular 126 
localization of the target protein; proteins that function in specific eukaryotic organelles such as 127 
mitochondria, chloroplasts and peroxisomes will generally benefit from expression hosts that 128 
possess such organelles (Fernández and Vega 2016); 2) types of lipids of host membranes; 129 
hydrophobic mismatch may occur due to differences in lipid bilayer composition and thickness 130 
between hosts, as highlighted for the overexpression of eukaryotic MP in bacteria, where the 131 
absence of sterols, sphingolipids and poly-unsaturated fatty acids in E. coli bilayers poses 132 
additional challenges to their proper folding (Snijder and Hakulinen 2016); 3) Construct size; 133 
proteins larger than 120 kDa are difficult to be efficiently expressed in E. coli, and are typically 134 
obtained in very low yields, as inclusion bodies or proteolytically degraded (Fernández and 135 
Vega 2016). 136 
To overcome the limitations displayed by these in vivo expression systems – toxicity, 137 
limited membrane space for MP functional folding and inefficient transport and membrane 138 
insertion mechanisms -, CFE systems have been reported, which rely on the use of prokaryotic 139 
and eukaryotic protein synthesis machinery and related elements to direct protein synthesis from 140 
added DNA or mRNA templates (He et al 2011; Henrich et al 2015; Zheng et al 2014). In a 141 
different way, the preparation of highly hydrophobic peptides representing functional parts of 142 
MPs foreseeing their application onto structural and functional studies can be attained via 143 
chemical synthesis (Baumruck et al, 2018). Previously, Fernández and Vega (2016) reported 144 
some recommendations on which expression host use for a particular protein.  145 
 146 
1.2. Upstream strategies to improve membrane protein expression levels and/or 147 
folding 148 
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Membrane protein research strongly rely on recombinant production, which is vital for 149 
obtaining high quantities of properly folded proteins for further biophysical and functional 150 
testing. While it is difficult to define a set of guidelines generally applicable to all MP,, here we 151 
review distinct strategies (according Figure 1) that have been used to increase MP expression 152 
and/or folding using E. coli, P. pastoris and mammalian cell-based systems (Summarized in 153 
Tables S1, S2 and S3 in Electronic Supplementary Information). 154 
 1.2.1. Escherichia coli 155 
 Escherichia coli expression systems have been largely investigated for recombinant 156 
protein production processes, although with a lower success rate for membrane proteins than for 157 
soluble proteins. Aiming to reverse this trend, researchers have driven their efforts to develop 158 
enhanced upstream stages encompassing optimizations at the genetic-level, strain engineering or 159 
culture conditions, which are reviewed in Table S1 (Electronic Supplementary Information). 160 
1.2.1.1. Genetic-level strategies 161 
 The expression of proteins outside their original context can pose additional constraints 162 
since they might contain codons that are rarely used in the desired host, come from organisms 163 
that use non-canonical code or contain expression-limiting regulatory elements within their 164 
coding sequence. The genetic code contains 61 nucleotide triplets (codons) to encode 20 amino 165 
acids and 3 codons to terminate translation, and such degeneracy enables many alternative 166 
nucleic acid sequences to encode the same protein. Moreover, the frequencies with which 167 
different codons are used vary significantly between different organisms, between proteins 168 
expressed at high or low levels within the same organism, and sometimes even within the same 169 
operon (Gustafsson et al 2004). Indeed, each organism seems to prefer a different set of codons 170 
over others, a phenomenon termed as codon bias (Quax et al 2015). Based on these 171 
observations, metrics for the frequency of optimal codons were proposed, such as the 172 
commonlly used codon adaptation index (CAI). The CAI for a certain organism is based on the 173 
codon usage frequency in a reference set of highly expressed genes, such as the ones encoding 174 
ribosomal proteins and the CAI for a specific gene can be determined by comparing its codon 175 
usage frequency with this reference set (Sharp and Li 1986; Quax et al 2015).  176 
Different codon biases are also correlated with the amount of the corresponding tRNAs, 177 
which vary between organisms; for example, eukaryotes commonly use the AGG codon for 178 
arginine, although it is rarely used in E. coli (Gustafsson et al 2004). If this exerts a negative 179 
effect on heterologous gene expression, then the use of the use of E. coli strains over-expressing 180 
rare tRNAs (which are commercially available) can improve the yields of target proteins, as 181 
previously shown for different constructs of connexin carboxyl-terminal domains attached to 182 
their 4th transmembrane domain (Kopanic et al 2013). 183 
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 Moreover, the more codons that a gene contains that are rarely used in the expression 184 
host, the less likely it is that the heterologous protein will be expressed at reasonable levels and 185 
low levels are exacerbated if the rare codons appear in clusters or in the N-terminal. A strategy 186 
to overcome this problem involves sequence re-design by changing the rare codons to codons 187 
that more closely reflect the codon usage of the host without modifying the amino acid sequence 188 
of the encoded protein (Gustafsson et al 2004). Automated codon optimization algorithms have 189 
been developed to design coding sequences optimized for increased expression in certain hosts 190 
and codon optimization services are currently offered by DNA synthesis companies, which 191 
often rely on confidential algorithms. These algorithms optimize codon usage by maximizing a 192 
gene’s CAI to match that of the expression host, along with optimizing for some sequence 193 
features such as GC content and avoidance of repeats and motifs such as ribonuclease 194 
recognition sites, transcriptional terminator sites, Shine-Dalgarno-like sequenes, and sequences 195 
that lead to strong mRNA secondary structures (Quax et al 2015). On-line tools to gene design 196 
such as the OPTIMIZER (http://genomes.urv.es/OPTIMIZER/) (Puigbo et al 2007) or to 197 
analyze codon usage including the CAIcal (http://genomes.urv.cat/CAIcal/) (Puigbo et al 2008) 198 
are currently available, among many others which make use of distinct optimization parameters 199 
(reviewed by Angov 2011; Gould et al 2014; Parret et al 2016). 200 
 Based on the rationale that changes in protein structure and function can occur after 201 
synonymous codon replacement and that protein structure is DNA sequence-dependent, 202 
alternative approaches for synonymous codon design such as the “codon harmonization 203 
algorithm” have been proposed, which adapts the codons in a way that the original codon 204 
landscape of the gene in the original host is maintained in the expression hosts (Angov et al 205 
2008; Quax et al 2015). The authors considered that protein synthesis and folding in E. coli is 206 
co-translational and that nucleotide sequence-dependent modulation of translational kinetics 207 
might influence nascent polypeptide folding. Therefore, in this approach, synonymous codons 208 
from E. coli were selected that match as closely as possible the codon usage frequency used in 209 
the native gene, unless empirical structure calculations show that the codons are associated with 210 
putative link/end segments which therefore should be translated slowly (Angov et al 2008). 211 
Claassens et al (2017) studied the performance of this codon harmonization algorithm and 212 
compared with the wild-type variant and optimized gene variants (resorting to proprietary 213 
GeneOptimizer algorithm from GeneArt) using different proton-pumping rhodopsins and 214 
enzymes from archaea, bacteria and eukarya. Codon harmonization was performed using a 215 
codon harmonizer tool (http://codonharmonizer.systemsbiology.nl) based on the harmonization 216 
algorithm initially proposed by Angov et al (2008), and uses the codon usage frequency tables 217 
for the native and expression hosts, based on all codons in the protein-coding genes annotated in 218 
NCBI genome assemblies as inputs. The “codon frequency landscapes” were generated and 219 
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were evaluated quantitatively based upon a proposed Codon Harmonization Index (CHI), in 220 
which a value close to 0 indicates a well-harmonized gene; all harmonized variants have a CHI 221 
< 0.1 while all codon-optimized and wild-type variants deviate further from the native codon 222 
landscape and consequently present CHI higher than that of harmonized variants (> 0.183). It 223 
was additionally observed that transcriptional tuning (in this case by changing the concentration 224 
of L-rhamnose) generally improves heterologous production of the distinct variants, although 225 
the concentration of rhamnose frequently differs among different codon usage variants of the 226 
same protein. In general, harmonization is beneficial for increasing membrane-embedded 227 
production compared to wild-type variants for some proteins, for which in this study the wild-228 
type CHI score is also highest (as in the case of leptosphaeria rhodopsin, CHI = 0.279). 229 
Moreover, when the codon landscape of the wild-type gene in E. coli largely deviates from the 230 
landscape in the native hosts, harmonization seems to be a promising approach for increasing 231 
MP production (Claassens et al 2017). Recent developments point out that irrespective the 232 
algorithm used, using a bicistronic design (in comparison with a monocistronic design) does 233 
improve protein production in E. coli as it may eliminate the translation initiation as the rate-234 
limiting step of the translation process (Nieuwkoop et al 2019). It should also be also remarked 235 
the importance of using updated codon usage tables. In this way, Athey et al (2017) reported a 236 
database (available at hive.biochemistry.gwu.edu/review/codon) aiming to present and analyse 237 
codon usage tables for every organism with public available sequencing data, and which is 238 
being routinely updated to keep up with the continuous flow of new data. 239 
Instead of whole sequence optimization, synonymous codon substitutions in the region 240 
adjacent to the AUG start may lead to significant improvements in expression, thus 241 
circumventing the need to consider whole sequence optimization (Nørholm et al 2013). Indeed, 242 
codon usage optimization of the N-terminal guarantee an efficient translation start, which have 243 
been proved to enhance human tetraspan vesicle protein /TVP) Synaptogyrin 1 expression in E. 244 
coli (Löw et al 2012). Recently, Saladi et al (2018) developed a data-driven statistical predictor 245 
named “IMProve”, which combines a set of sequence derived features resulting in an IMProve 246 
score. As this value increases, there is also an increase in the probability of success, i. e. 247 
selecting a MP that expresses in E. coli. Currently, the characterization of an integral MP 248 
involves the identification and testing of multiple homologs or variants for expression and the 249 
predictive power of “IMProve” enables to enrich for positive outcomes by 2-fold by providing a 250 
low-barrier-to-entry (Saladi et al 2018).  251 
Throughout the years, codon optimizations have been performed on a first screening 252 
basis aiming an increase in the yields of properly folded MP, and with much success without 253 
noticeable changes in protein structure and function. However, the increasing understanding of 254 
the principles of codon bias and mechanisms of translation have been unveiling yet unknown 255 
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features. In fact, synonymous codons are known to potentially affect protein expression at 256 
various levels and increasing evidences have been showing that translation is affected, leading 257 
to dramatic alterations in the conformation and processing of some proteins (Mauro 2018). 258 
Overall, codon optimization seems appropriate for some applications, e.g. protein evolution and 259 
increasing the expression and/or activity of industrial enzymes; however, for recombinant 260 
expression of proteins for therapeutics, we should also aim to maintain the conformation and 261 
processing of the natural protein sequences (Mauro 2018). 262 
In E. coli and due to the higher copy number of the target gene usually achieved with 263 
plasmid-based systems, recombinant proteins are typically expressed in E. coli from medium to 264 
high plasmid copy number (PCN) based on a Col1E derived origin of replication, (Baneyx 265 
1999). The PCN is correlated with the recombinant gene dosage and can be accurately 266 
determined by quantitative Polymerase-Chain Reaction (qPCR) procedures (Lee et al 2006; 267 
Martins et al 2015). A recent study by Jensen et al (2017) provided a systematic approach to 268 
identify gene disruptions that increase MP expression in E. coli and can be used to improve 269 
expression of any protein that poses a cellular burden. 270 
Based on the combination of some the above-mentioned strategies, namely “codon 271 
harmonization”, use of low copy number vectors with moderate strength, suitable leader 272 
sequences, and optimization of cell culture conditions, increased targeting to E. coli outer 273 
membrane of Chlamydia trachomatis major outer membrane protein was observed and the 274 
formation of inclusion bodies avoided (Wen et al 2016). On the other hand, prokaryotic 275 
expression vectors using the rhaB promoter which are almost completely repressed until 276 
induced can be suitable for the expression of toxic proteins (Giacalone et al 2006).  277 
 278 
1.2.1.2. Strain engineering 279 
Remarkable enhancements in MP expression from E. coli-based systems have been 280 
achieved with engineered strains due to their improved ability to cope with MP-induced 281 
toxicity, more efficient chaperone pathways, different substrate uptake rates or reinforced 282 
integrity of intracellular structures, e.g. periplasmic space. Earlier observations have shown that 283 
protein (including but not limited to MP) overexpression driven by the T7 RNA polymerase in 284 
E. coli BL21 (DE3) cells can be limited or prevented by cell death (Miroux and Walker 1996). 285 
In this regard, by plating E. coli BL21(DE3) cells expressing toxic proteins (oxoglutarate-286 
malate carrier protein from mitochondrial membranes and subunit b of bacterial F-ATPase) in 287 
agar plates containing IPTG (for a review of these methods, please refer to Schlegel et al 2017), 288 
Miroux and Walker (1996) were able to isolate two isolate two survivors, the mutant host 289 
strains C41 (DE3) and C43 (DE3), which have become known as the “Walker strains” and 290 
widely used for MP overexpression. Latter studies showed that mutations in the lacUV5 291 
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promoter governing expression of T7 RNA polymerase are the key to improved MP 292 
overexpression characteristics of C41 (DE3) and C43 (DE3) strains (Wagner et al 2008). The 293 
rationale behind the application of BL21 (DE3) for protein production was that T7 RNA 294 
polymerase transcribes faster than E. coli RNA polymerase and more mRNA results in more 295 
overexpressed protein. However, for most MP, strong overexpression leads to the production of 296 
more protein than the Sec translocon can process, thus impairing their insertion into the 297 
membrane, which thereby highlights the need to tune MP expression aiming to avoid Sec 298 
saturation (Wagner et al 2008). Based on these observations, Wagner et al (2008) engineered a 299 
new BL21 (DE3) derivative strain designated Lemo21 (DE3) wherein the activity of the T7 300 
RNA polymerase can be precisely controlled by its natural inhibitor T7 lysozyme, which 301 
plasmid was under the control of the well-titratable rhamnose promoter (Wagner et al 2008; 302 
Schlegel et al 2012). The expression of insertase YidC fused to GFP in the cytoplasmic 303 
membrane of Lemo21 (DE3) strain was maximal at 1000 µM rhamnose, and was additionally 304 
demonstrated that this strain is compatible with auto-induction media (Schlegel et al 2012). 305 
More recently, Baumgarten et al (2017) isolated the mutant56 (DE3) [Mt56 (DE3)] from 306 
BL21(DE3) expressing YidC C-terminally fused to GFP, which allows to evaluate if the 307 
produced proteins are being targeted to the cytoplasmic membrane. The authors found that this 308 
strain produced several MP in higher levels than C41 (DE3), C43 (DE3) or BL21 (DE3), and its 309 
improved performance is attributed a mutation in the gene encoding T7 RNA polymerase in 310 
position 305 (C:G – A:T transversion), leading to a single amino acid exchange in T7 RNA 311 
polymerase (A102D). Rather than lowering T7 RNA polymerase levels [as with C41 (DE3) and 312 
C43 (DE3)], the A102D mutation weakens the binding of the T7 RNA polymerase to the T7 313 
promoter governing target gene expression (Baumgarten et al 2017).  314 
Envisaging an increase in the amount of membrane-embedded and correctly folded 315 
mammalian GPCRs (G protein-coupled receptor), Skretas et al (2012) screened libraries of 316 
genomic fragments using two different flow cytometric assays, namely by monitoring the 317 
binding of a fluorescently labeled ligand to active GPCR and the fluorescence of GPCR-GFP 318 
fusions. These screens allowed the isolation of the genes nagD (encoding the ribonucleotide 319 
phosphatase NagD), nlpDΔ (encoding a C-terminal truncation of the putative outer membrane 320 
lipoprotein NlpD) and the three-gene cluster ptsN-yhbJ-npr (encoding three proteins of the 321 
nitrogen phosphotransferase system) and was additionally proved that their co-expression leads 322 
to a marked increase of membrane-integrated and well-folded GPCR and also a prokaryotic MP 323 
(Skretas et al 2012). In general, it seems that the enhanced effect is not due to a direct 324 
interaction of these genes with the target proteins, but instead by indirect effects, namely 325 
induction of stress responses or changes in the composition of the bacterial periplasm (Skretas 326 
et al 2012). Foreseeing the identification of genes whose coexpression can supress MP-induced 327 
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toxicity, a genome wide screen identified two potent suppressors, namely djlA (encoding the 328 
membrane-bound DNAk cochaperone DjlA) and rraA (encoding RRaA), an inhibitor of the 329 
mRNA-degrading activity of the E. coli RNase E (Gialama et al 2017). E. coli strains 330 
coexpressing djlA or rrA, referred as SuptoxD and SuptoxR, respectively, strains were found to 331 
have a consistent behavior regarding an enhancement production of distinct MP, namely from 332 
mammalian and bacterial origin and with different topologies, and perform better than other 333 
commercially available strains (Gialama et al 2017). 334 
Another method to mitigate the toxic effect of overexpression is “restrained 335 
expression”, in which the production of T7 RNA polymerase and the target gene are controlled 336 
by distinct promoters, respectively the arabinose promoter and T7lac promoter (Narayanan et al 337 
2011). Under “restrained expression” conditions, namely addition of minimal quantities of 338 
arabinose (0.01 %) to produce low levels of T7 RNA polymerase and omission of IPTG, aiming 339 
to explore the occasional derepression ocurring at the lac operator site of T7lac promoter, an 340 
increase of 5 to 25-fold in the expression of homologs of cardiac Na+/Ca2+ exchanger were 341 
obtained, in comparison with IPTG-induction. Moreover, improvements were also found per 342 
unit of OD600 nm of cells, indicating that “restrained expression” is associated with decreased 343 
cellular toxicity. In general, by reducing the frequency of transcription initiation, protein 344 
production is slower, which is unlikely to saturate the biogenesis machinery, thereby providing 345 
the explanation for the decreased cytoplasmic aggregation and the attendant cytotoxicity when 346 
comparing “restrained” and “rapid” (induction with arabinose and IPTG) expression (Narayanan 347 
et al 2011). Nannenga and Baneyx (2011) reported the expression of MP in Δtig strains 348 
[Transcription factor (TF) deficient] which due to TF inactivation, the signal recognition 349 
particle (SRP) has unimpeded access to the nascent transmembrane segment, thus resulting in 350 
targeting of MP to the inner membrane, while Yidc overproduction promotes MP insertion and 351 
folding in the lipid bilayer.  352 
A distinct approach aiming an enhancement in the production of soluble integral 353 
membrane spanning proteins relied on engineering E. coli wild type AF1000 to reduce the 354 
growth rate/substrate uptake rate, accomplished by deletions in the phosphoenolpyruvate 355 
carbohydrate:phosphotransferase system (PTS), which is responsible for the uptake of various 356 
sugars in E. coli (Backlund et al 2011). Distinct mutant strains unable to take up glucose were 357 
obtained, and characterized as follows: a defective enzyme IIABMan, which unspecifically 358 
controls the uptake of mannose but also allows glucose passage (ptsM); a defective enzyme 359 
IIBCGlc (ptsG), specific for glucose uptake, and the double mutant (ptsG, ptsM). As a result of 360 
the removal of ptsG, these mutants display a reduced growth rate at high glucose concentrations 361 
but they can grow to high cell densities [although more slowly than BL21(DE3)] since they 362 
produce no acetic acid. In general, these strains were able to produce some of the MP in study in 363 
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relatively larger quantities than BL21 (DE3) but whether this enhanced ability is due to the low 364 
growth rate or the lack of acetic acid production was not totally clarified (Backlund et al 2011). 365 
Finally, based on the previously published protocols used for MP structure 366 
determination, Bruno Miroux research group (Hattab et al 2015) revealed the preferences of E. 367 
coli strain-vector combinations for an optimal use of this expression system and successful 368 
production of MP. At that time (June 2014), they found that for the determination of 141 unique 369 
non E. coli MP structures, 163 expression vector/bacterial hosts were applied, from which T7 370 
promoter was dominant (63 %), followed by the arabinose, tac and T5 promoter based 371 
expression systems (17 %, 9% and 7%, respectively). Moreover, within T7 based expression 372 
systems, the host BL21 (DE3) was the most employed, followed by the mutants C43 (DE3) and 373 
C41 (DE3), accounting with 40, 18 and 16 MP structures, respectively. Overall, this study 374 
shows that C41 (DE3) and C43 (DE3) mutants together with the parental host BL21 (DE3) have 375 
contributed significantly for the success of bacterial expression systems in structural biology of 376 
MP, in which the mutants have been preferably applied for the production of difficult to express 377 
MP. Additional remarks show that IPTG concentration and growth temperature are important 378 
parameters complementary to the choice of a bacterial host, and that a high copy number vector 379 
should be used with C41 (DE3) to take advantage of the strength of the T7 based expression 380 
system, whereas for more difficult MP, the mutant C43 (DE3), especially with low copy number 381 
plasmids allows to attenuate the transcription of the target gene (Hattab et al 2015). 382 
 383 
1.2.1.3. Protein fusion methodologies 384 
Aiming to increase MP solubility and folding or to easily track their expression levels, 385 
MP have been expressed with distinct fusion partners (tags) such as SUMO (small ubiquitin-386 
related modified, MBP (maltose-binding protein) or GFP (green fluorescent protein), 387 
synthesized either as translational (Zuo et al 2005; Liu et al 2012) or transcriptional fusions 388 
(Marino et al 2015). In translational fusions, the N-terminal fusion partners are part of the same 389 
protein chain of the membrane protein and can be cleaved off after protein production if any 390 
proteolytic cleavage site is introduced. On the other hand, transcriptional fusions exploit the 391 
presence of an additional RNA sequence upstream of the mRNA sequence of the target MP, 392 
leading to a bicistronic mRNA (Marino et al 2017). As a result, the ribosome produces two 393 
distinct protein products during translation, thereby eliminating the need to enzimatically 394 
remove the fusion protein during purification (Marino et al 2015). As opposed to translational 395 
fusions, transcriptional fusions do not lead to a physical linkage of the fusion protein and MP, 396 
which eliminates potential interference of the fusion partner in proper folding and functionality 397 
of the target protein (Marino et al 2015; Marino et al 2017). Distinct solubility enhancer tags 398 
such as SUMO, MBP, TrxA (thioredoxin) or GST (glutathione-S-transferase) with sizes ranging 399 
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from 7 to 495 amino acids have been reported (Costa et al 2014). Based on the knowledge that 400 
ubiquitin exerts chaperoning properties on fused proteins, translational fusions with the 401 
ubiquitin-like protein SUMO were successfully explored towards an enhancement of the 402 
solubility and biological activity of the severe acute respiratory syndrome coronavirus (SARS-403 
CoV) MP and 5-lipoxygenase-activating protein (FLAP) (Zuo et al 2005). An additional 404 
advantage is that SUMO fusion can be cleaved with high specificity by SUMO protease 1 and 405 
generates a protein with the native N-terminal (Zuo et al 2005). On the other hand, Liu et al 406 
(2012) evaluated different constructs resorting translational fusions of selenoprotein K 407 
envisaging its overexpression in E. coli better results were achieved with cytoplasmic MBP over 408 
periplasmic MBP and SUMO (Liu et al 2012). In addition to the chaperoning properties 409 
displayed by MBP and SUMO, these fusion partners also protect the target proteins from 410 
degradation by promoting their translocation from the cytosol to the cell membrane (MBP) and 411 
nucleus (SUMO) where less protease content exists (Costa et al 2014). Noteworthy, beyond an 412 
increase in the target protein solubility – solubility enhancer -, the natural affinity of MBP 413 
towards immobilized amylose resins can also be explored as a purification tool; however, this 414 
binding is highly dependent on the nature of the target protein as it can block or reduce the 415 
amylose interaction (Costa et al 2014). Translational fusions encompassing a solubility 416 
enhancer tag – MBP – and an affinity tag – His-tag – to accomplish the dual purpose of 417 
increasing the solubility of MP while exploring their high affinity onto specific affinity 418 
chromatographic matrices for purification are feasible, as previously reported for selenoprotein 419 
K (Liu et al 2012). A distinct strategy envisaging to target proteins to E. coli inner membrane 420 
reported by Luo et al (2009) is based on the fusion of a novel partner (P8CBD) to prokaryotic 421 
and eukaryotic MP. P8CBD was carefully designed and the DNA encoding 58 amino acid 422 
residues of E. coli Signal peptidase to provide a second transmembrane segment aiming to 423 
extend the protein fusion junction into the periplasmic space, which was selected based on its 424 
ability to efficiently establish the desired orientation within the inner membrane (Luo et al 425 
2009). A chitin binding domain was also engineered to act as an optional affinity tag or 426 
detection epitope while at the fusion junction an enterokinase cleavage site and corresponding 427 
FLAG epitope were also incorporated. Overall, by making use of the Signal Recognition 428 
Particle (SRP) membrane targeting pathway, the expression and membrane translocation of 429 
P8CBD fusion proteins is enhanced (Luo et al 2009). The location of translational fusions is an 430 
important factor since they can promote different effects when placed at the N-terminus or C-431 
terminus (Costa et al. 2014). This is better exemplified by the attachment of affinity 432 
oligohistidine tags to the periplasmic terminus of E. coli transporters, which is detrimental for 433 
their expression (Rahman et al 2007). A possible explanation for this relies on a possible 434 
interference of oligohistidine sequences with the proper translocation of the adjacent segments 435 
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of the protein across the membrane during biosynthesis once the charge distribution across 436 
transmembrane segments is known to have a profound effect on their orientation (Rahman et al 437 
2007). The optimum location of the tag is also influenced by the topology of MP. Although Nin-438 
Cin topologies dominate the membrane proteomes of most organisms, one or both termini of a 439 
substantial fraction of MP are located on the extracellular or periplasmic side of the membrane, 440 
for which tandem Strep-tag II sequences or oligohistidine tags fused to MBP and a signal 441 
sequence should be applied (Ma et al 2015). 442 
Unlike translational fusions, there is no need to proceed to the enzymatic removal of 443 
transcriptional tags once there is no physical linkage between the target MP and the fusion tag 444 
(Marino et al 2017). Marino et al (2015) compared the expression of different proteins using 445 
translational and transcriptional fusions of genes coding for the fusion proteins Mistic 446 
(membrane-integrating sequence for translation of inner membrane proteins from Bacillus 447 
subtilis), SUMO and a shorter version of YBeL respectively, mstX, sumo and ybeL. They 448 
created bicistronic mRNA cassettes where the stop codon of the preceding gene (mstX, sumo, 449 
or ybeL) overlaps with the start codon of the target protein, thereby mimicking a common 450 
genetic organization observed for bacterial operons (Marino et al 2015). They observed an 451 
enhanced expression of MP via transcriptional fusions with mstX and ybeL, and the cause of this 452 
effect cannot be atributted to re-initiation of ribosomes, but instead is most likely atributted to 453 
the enhanced translation initiation by a more favorable secondary structure in the transcript 454 
(Marino et al 2015).  455 
Another major breakthrough within this field in many expression systems was made 456 
through fusion of fluorescent reporters such as GFP to the target MP (Drew et al 2001; 457 
Goehring et al 2014; Gul et al 2014), which behaves as a folding indicator of the target MP and 458 
allowing to infer on their expression levels. This process usually relies on fusing GFP to the C-459 
terminal of proteins; since GFP only becomes fluorescent if the MP integrates in the 460 
cytoplasmic membrane, it allows to distinguish between MP overexpression in the cytoplasmic 461 
membrane and in inclusion bodies at any stage during overexpression, solubilization and 462 
purification (Drew et al 2001; Drew et al 2006). In addition, GFP will only become fluorescent 463 
if the MP has a Cin topology, i. e. the C-terminus is cytoplasmic (Drew et al 2006). Noteworthy, 464 
fluorescence in whole cells can be detected with a detection limit as low as 10 µg of GFP per 465 
liter of culture, and can also be determined in standard SDS polyacrylamide gels with a 466 
detection limit of less than 5 ng of GFP per protein band (Drew et al 2006). Also based on the 467 
use of GFP as a fusion partner, Nji et al (2018) recently reported a fluorescence detection size-468 
exclusion chromatography-based thermostability assay (FSEC-TS) that allows measuring 469 
apparent melting temperatures (Tm) of MP in the absence and presence of distinct lipids, which 470 
can be helful to identify which lipids can have a stabilizing effect for a particular target.  471 
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In addition to GFP, Gul et al (2014) reported the translational fusion of the 472 
erythromycin resistance protein (23 S ribosomal RNA adenine N-6 methyltransferase, ErmC) 473 
(in tandem with GFP) to the C-terminus of different bacterial MP wherein GFP fluorescence 474 
was applied to report the folding state of the target protein and ErmC to select for increased 475 
expression. Evolved strains termed NG were selected in increasing concentrations of 476 
erythromycin which carry out a mutation in hns gene, and the degree of MP expression 477 
correlates with the severity of hns mutation, although its deletion resulted in an intermediate 478 
expression. Overall, in each NG strain, the amount of fluorescent (folded) protein and the ratio 479 
of folded over misfolded protein increased up to 10-fold relative to the parental strain 480 
BW25113B (Gul et al 2014). Another approach to easily detect the expression levels of MP was 481 
reported by Hsu et al (2013) which is based on the use of mutated bacteriorhodopsin from 482 
Haloarcula marismortui as a fusion partner, and which unlike GFP, MP overexpression can be 483 
detected by naked eye or by directy monitoring their optical absorption.  484 
Aiming to select mutants of E. coli that improve MP expression, Massey-Gendel et al 485 
(2009) reported an approach that relies on fusing the targeted MP to a C-terminal selectable 486 
marker that confers a drug resistance phenotype (Massey-Gendel et al 2009). The rationale 487 
behind this strategy is that the production of the selectable marker and survival on selective 488 
media is linked to expression of the targeted MP, namely when the c-terminus is in the 489 
cytoplasm. After the selection of the mutants, curing of isolated mutants is performed by in vivo 490 
digestion with the homing endonuclease I-CreI (Massey-Gendel et al 2009). 491 
Recently, Mizrachi et al (2015) developed a technique called SIMPLEx (Solubilization 492 
of Integral MP with high Levels of Expression), which allows the direct expression of soluble 493 
products in living cells by fusing the target MP with the carboxyl terminal of apolipoprotein A-1 494 
(ApoAI*). In addition, a highly soluble “decoy” protein from Borrelia burgdorferi, namely the 495 
outer surface protein A (MBP lacking its N-terminal signal peptide can also be used) was fused 496 
to the N-terminus to prevent the E. coli secretory pathway to introduce the protein in inner 497 
membrane. Acting as an amphipatic proteic “shield” which sequester MP from water, ApoAI* 498 
promotes the solubilization of structurally diverse MP (bitopic α-helical, polytopic α-helical and 499 
polytopic β-barrel) and yields of EmrE-solubilized dimers and tetramers (EmrE basic functional 500 
units) ranged between 8 and 10 mg/L of culture after Nickel affinity chromatography. ApoAI*-501 
solubilized EmrE (E. coli ethidium multidrug resistance protein E) was amenable to structural 502 
characterization including negative staining electron microscopy, dynamic light scattering and 503 
SAXS (Small angle X-ray scattering) data collection (Mizrachi et al 2015). 504 
 505 
 1.2.2. Pichia pastoris 506 
1.2.2.1. Genetic-level strategies 507 
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 Yeasts and particularly P. pastoris are highly attractive alternatives for MP expression 508 
as they represent low-cost cultivation and high-quantity production platforms, meeting the 509 
demand for criteria of safety and authentically process proteins (Emmerstorfer-Augustin et al 510 
2019). Pichia pastoris systems usually rely on the use of integrative plasmids containing the 511 
gene of interest which are integrated into the yeast genome, generating stable production strains 512 
(Dilworth et al 2018). Moreover, protein production is usually accomplished resorting the 513 
alcohol oxidase promoter (AOX), which is inducible by methanol and depending on the 514 
functionality of 1 or both aox genes, recombinant strains may present a MutS or Mut+ phenotype 515 
exhibiting different growth behaviors (in methanol) and different methanol requirements for 516 
induction. Other commonly used promoter is the constitutive glyceraldehyde-3-phosphate 517 
(GAP) dehydrogenase promoter (Gonçalves et al 2013). 518 
In the last years, studies have shown that distinct recombinant gene dosages and codon 519 
usage optimizations greatly influence MP expression levels in P. pastoris. As mentioned above, 520 
P. pastoris expression systems usually rely on expression plasmids that are integrated into the 521 
yeast genome and multi-copy clones – the so-called “jackpot clones” –, can be selected 522 
experimentally by screening several colonies in increasing concentrations of antibiotic 523 
(Dilworth et al 2018). Nordén et al (2011) performed a two-step antibiotic selection, initially 524 
with 100µg/mL zeocin and then with higher concentrations, from which they isolated multi-525 
copy clones and observed that the expression of different aquaporins strongly respond to an 526 
increase in recombinant gene dosage, independently of the amount of protein expressed from a 527 
single gene copy clone. However, despite higher recombinant gene dosages can lead to higher 528 
titers of recombinant proteins, this correlation is not always linear and strains with low copy 529 
number may be preferred (Aw and Polizzi 2013, Dilworth et al 2018). Aiming to exclude 530 
possible false-positives while establishing accurate correlations, along with the levels of the 531 
target protein, the recombinant DNA levels must be evaluated, for which qPCR protocols have 532 
been reported using pPICZ vectors (Nordén et al 2011) and resorting to SYBR Green or 533 
TaqMan (Abad et al 2010). Another way to improve human aquaporins expression in P. 534 
pastoris is based on the optimization of the nucleotide sequence around the initial ATG based 535 
on the use of mammalian Kozak’s sequence consensus (Oberg et al 2009). The prevalence of a 536 
guanine at the first position of the second codon after ATG encodes small amino acids such as 537 
alanine (GCN) or on a smaller extent glycine (GGN), which are crucial to ensure an efficient 538 
cleavage of the initiator methionine (Oberg et al 2009). In most cases, this has a positive impact 539 
on aquaporins expression, while the opposite seems to be observed when a thymine is at 540 
position +6 (Oberg et al 2009). 541 
The codon bias problem in MP production from P. pastoris have also been addressed. 542 
Considering that the translation efficiency of more highly expressed genes may be especially 543 
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sensitive to codon usage, Bai et al (2011) generated a codon usage table specific for highly 544 
expressed genes in P. pastoris and adjusted the sequence of P-glycoprotein-encoding mdr3 545 
gene, taking into account relative codon frequencies for each amino acid, as well as optimizing 546 
GC content and controlling for mRNA instabilities. Using the optimized gene construction, the 547 
authors obtained an increase of three-fold in the expression yields in comparison with the wild-548 
type gene of P-glycoprotein and similar secondary and tertiary structures between the proteins 549 
from the different constructs, emphasizing the effectiveness of the gene optimization approach 550 
developed (Bai et al 2011). 551 
Expression resorting fusion partners has been applied since the early beginning of MP 552 
expression in P. pastoris. Talmont et al (1996) expressed the µ-opioid receptor fused with S. 553 
cerevisiae α-mating factor aiming to facilitate the translocation of the receptor to the membrane. 554 
Distinctly, it was shown that the presence of the α-mating factor can be detrimental for the 555 
expression of human histamine H1 receptor in P. pastoris (Shiroishi et al 2011), which can be 556 
due to incomplete processing by the endogenous Kex2 protease, leading to a heterogenous 557 
population. A way to overcome this problem is by introducing a proteolytic cleavage site 558 
upstream of the gene (Byrne 2015). 559 
The application of GFP as a fusion partner has been extensively used to screen for high-560 
yield expressing clones spanning the most popular hosts for MP production including P. 561 
pastoris. Brooks et al (2013) reported a fluorescent-based induction plate assay aiming the 562 
simultaneously screening of P. pastoris clones for the expression of aquaporin 4 and 563 
homologues of ER associated MP phosphatidylethanolamine N-methyltransferase in which 50 564 
and 48 clones were respectively screened. The plates were imaged under blue light and the 565 
colony fluorescence quantified using Mean Gray Values and revealed a distribution of 566 
fluorescence related to protein expression, ranging from background to high, being additionally 567 
demonstrated that there is a good correlation between plate expression and liquid culture 568 
expression (Brooks et al 2013).  569 
In addition to secreted proteins, MP can also enter the secretory pathway but unlike 570 
them, MP remain in the ER, Golgi or the plasma membrane (Vogl et al 2014). Due to MP 571 
overexpression, unfolded and misfolded proteins can accumulate in the ER, thereby triggering 572 
the unfolded protein response (UPR). The UPR signaling pathway involves the kinase/RNase 573 
Ire1 that when activated initiates an unconventional splicing reaction of the HAC1 mRNA that 574 
ends with the removal of the intron and subsequent translocation of Hac1p to the nucleus 575 
(Guerfal et al 2010). Guerfal et al (2010) showed for the first time the beneficial effect of co-576 
expressing Hac1p with the adenosine A2A receptor, namely in terms of a better processing of 577 
the alpha-mating factor, thus improving the homogeneity of the obtained MP fractions. Later, 578 
Vogl et al (2014) performed a transcriptomic analysis of P. pastoris CBS 7435 overexpressing 579 
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different classes of MP (mitochondrial, ER/Golgi and plasma-membrane localized) and found 580 
that proteins targeted to the mitochondrial membrane mainly alter the energy metabolism while 581 
the gene coding for Hac1p was upregulated in strains expressing the CMP-Sialic acid 582 
transporter, which localizes to ER and Golgi. Interestingly, they found that the overexpression 583 
of the spliced variant of Hac1 led to an increase of 1.5-fold to 2.1-fold in the expression of ER-584 
resident MP tested (Vogl et al 2014) 585 
 586 
1.2.2.2. Strain engineering and improved processing conditions 587 
Pichia pastoris expression strains are derivatives of NRRL-Y 11430 (Northern 588 
Regional Research Laboratories, Peoria, IL, USA) (Cregg et al 2000) encompassing distinct 589 
genotypes/phenotypes, and generally most of them have been applied for MP production, 590 
namely X33 (wild-type/Mut+) (Oberg et al 2009), KM71H (arg4aox1::ARG4/MutS Arg+) (Bai 591 
et al 2011), GS115 (his4/Mut+ His-) (Guerfal et al 2010) and also protease defficient strains such 592 
as SMD1163 (pep4 prb1 his4/Mut+ His-) (André et al 2006). 593 
The requirement of association with cellular membranes and the type of membranous 594 
lipids can be critical for successfully achieving the goal of producing a recombinant MP in a 595 
functional active form, given their close spatial interactions (Emmerstorfer-Augustin et al 596 
2019). Plasma membranes are generally constituted by a mixture of lipids including 597 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, 598 
phosphatidic acid, sphingolipids and sterols (van der Rest 1995). As the composition and 599 
molecular properties of the lipids differ from lower to higher eukaryotes, the distinct type of 600 
sterols in yeasts and mammalians, respectively ergosterol and cholesterol, can represent a 601 
bottleneck for the heterologous expression of mammalian proteins in yeasts (Emmerstorfer-602 
Augustin et al 2019; Hirz et al 2013). Therefore, aiming an improvement in the functional 603 
expression, stability and translocation of Na+/K+ ATPases α3β1 isoform, Hirz et al (2013) 604 
reprogrammed P. pastoris (strain CBS7435 Δhis4 Δku70) to mainly produce cholesterol instead 605 
of ergosterol. This was accomplished by replacing ERG6 (encodes the sterol C-24 methyl 606 
transferase) and ERG5 (encodes the sterol C-22 desaturase) by constitutive DHCR7 and 607 
DHCR24 (dehydrocholesterol reductases) overexpression cassetes, envisaging an efficient 608 
conversion of cholesta-5,7,24(25)-trienol to cholesterol (Hirz et al 2013; Emmerstorfer-609 
Augustin et al 2019). The authors found that the expression levels of the target ATPase 610 
significantly increased with induction time in the cholesterol-forming strain compared to the 611 
wild-type strain, indicating a positive influence of the altered sterol composition on the stability 612 
of the synthesized MP (Hirz et al 2013). Another example of “humanizing” P. pastoris for the 613 
expression of human proteins consists of the disruption of an endogenous glycosyltransferase 614 
gene (OCH1) and the stepwise introduction of heterologous glycosylation enzymes, envisaging 615 
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to largely eliminate the fungal N-type N-glycosylation while avoiding a considerable 616 
heterogeneity in the produced protein and their rapid clearance if therapeutics is the main goal 617 
(Jacobs et al 2009; Laukens et al 2015). This strategy is generally referred as GlycoSwitch® and 618 
can be applied in wild-type strains (e.g. GS115) or GlycoSwitch® Man 5 strain wherein the first 619 
glyco-engineering step was already introduced, and encompasses distinct glyco-engineering 620 
steps based on the transformation of P. pastoris with GlycoSwitch® vectors under previously 621 
reported protocols (Jacobs et al 2009; Laukens et al 2015). Currently, these vectors are 622 
commercially available from BioGrammatics (Carlsbad, USA) under the licence from Research 623 
Corporation Technology (RCT). 624 
Envisaging to prevent a possible inhibition of the AOX promoter by glycerol, Pichia 625 
pastoris AOX-based bioprocesses usually encompass an initial stage of growth in glycerol 626 
followed by methanol induction, which is often cumbersome specially when glycerol 627 
consumption cannot be monitored (Lee et al 2017). Earlier observations with KM71H strains 628 
demonstrating that leaky expression is not a critical factor once the target expression per cell 629 
mass is mostly dependent on the starting glycerol concentration of the media and to a lesser 630 
degree by yeast nitrogen base (YNB) and biotin concentrations. Moreover, as even in the 631 
presence of a methanol concentration higher than the glycerol concentration no target 632 
expression was detected until about 24 h of incubation, Lee et al (2017) developed the Buffered 633 
extra-YNB Glycerol Methanol (BYGM) auto-induction media (100 mM potassium phosphate 634 
pH 6.0, 2.68 % w/v YNB, 0.4 % v/v glycerol, 0.5 % v/v methanol and 8 x 10-5 % w/v biotin). 635 
This auto-induction method avoids the traditional media-swabbing step and it is additionally 636 
claimed that it can be applied to MutS and Mut+ strains and distinct MP without compromising 637 
their expression yields (Lee et al 2017). The use of additives in culture media have also been 638 
reported to increase MP expression levels. André et al (2006) reported increased expression 639 
levels of functional GPCR resorting the optimization of growth temperature and 640 
supplementation of culture media with specific GPCR ligands, histidine, and dimethylsulfoxide 641 
(DMSO). As DMSO can modify the physical properties of membranes and upregulates genes 642 
involved in lipid synthesis (Murata et al 2003), it can have a positive effect on MP in yeast and 643 
is additionally pointed out that by permeabilizing membranes, it can have an indirect effect by 644 
facilitating the entry of other ligands to intracellular compartments where they reach the 645 
receptor populations (André et al 2006). The beneficial effect of DMSO is not restricted to 646 
GPCR as Pedro et al (2015) reported an increase of 1.8-fold in the enzymatic activity of human 647 
membrane-bound catechol-O-methyltransferase (MBCOMT), achieved by adding 5% v/v 648 
DMSO. Subsequently, the artificial neural network modelling of the methanol induction phase, 649 
accomplished by tailoring the temperature, DMSO concentration and methanol constant flow-650 
rate allowed an improvement of 1.53 fold in the enzyme activity over the best conditions 651 
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performed in the DoE step (Pedro et al 2015). In addition, the direct solubilization of MP whole 652 
cells (yeasts protoplasts) may help to decrease the amount of misfolded and/or aggregated 653 
proteins that are co-extracted with the properly folded protein (Hartmann et al 2017). 654 
 655 
 656 
 657 
 1.2.3. Mammalian cell lines 658 
General approaches and factors for successful optimization of mammalian-based 659 
systems for recombinant protein production have been reviewed elsewhere (Andréll and Tate 660 
2013; Almo and Love 2014; Hacker and Balasubramanian 2016; McKenzie 2018). In this sub-661 
section, we will generally focus our attention in strategies that have been proved to be 662 
particularly useful for MP, foreseeing improved expression and/or folding and also those 663 
enabling biochemical and functional studies of these relevant drug targets (summarized in Table 664 
S3). 665 
Distinct mammalian cell lines have been applied for MP production such as HEK293, 666 
baby hamster kidney cells (BHK-21), monkey kidney fibroblast cells (COS-7) and CHO 667 
(Andréll and Tate 2013), but HEK293 and CHO are more commonly applied, either in transient 668 
or stable transfection (Lyons et al 2016).  669 
The levels of expression of MP in transiently transfected mammalian cell lines are 670 
affected by the plasmid size, the amount of plasmid used per transfection, the strength of the 671 
promoter, the cell type, the efficiency of the transfection and potentially the toxicity of the 672 
transfection reagent (Andréll and Tate 2013). Using design of experiments, Bollin et al (2011) 673 
optimized the yields of an antibody resorting to transient gene expression and found that the 674 
DNA concentration can be maintained at relatively low concentrations (1 mg/L range). Indeed, 675 
envisaging functional expression of a MP in the plasma membrane, the ratio of plasmid DNA 676 
added per reaction can be a crucial factor (particularly if a strong promoter is used), once too 677 
much plasmid can lead to intracellular accumulation of the protein and potentially misfolded 678 
(Andréll and Tate 2013). Both CHO and HEK cell lines have been extensively used in transient 679 
transfection, advances in serum free media formulations allow their growth to high-cell 680 
densities, which can greatly facilitate the purification of target proteins (Almo and Love 2014; 681 
McKenzie et al 2018). An alternative approach increasingly applied as a gene delivery 682 
methodology for protein production is based on the use of lentivirus, owing to their ability to 683 
transduce a broad range of cell types (Bandaranayake and Almo 2014). Aiming to combine the 684 
ease and speed of transient transfection with the robust expression of stable cell lines, Elegheert 685 
et al (2018) constructed a lentiviral plasmid suite around the transfer plasmid pHR-CMV-TetO2 686 
that is designed for large-scale protein expression from HEK293 cell lines and allows 687 
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subcloning of cDNA from the plasmid PHLsec usually applied for transient transfection. This 688 
approach was tested in both soluble and MP, and in general, the typical lead time for protein 689 
production using this strategy is of 3-4 weeks and approximately three- to tenfold improvement 690 
in protein production yield per cell was obtained, in comparison with transient transfection 691 
(Elegheert et al 2018). 692 
Unlike transient transfection, stable gene expression requires the screening of clonal cell 693 
lines, which is typically achieved through limited dilution involving serial dilution of recently 694 
transfected cells and seeding on tissue culture plates with antibiotic-resistance media. 695 
Subsequently, different colonies are individually transferred to 24-well plates and scaled-up 696 
(Andréll and Tate 2013). For a review of selection methodologies, please refer to Browne and 697 
Al-Rubeai (2007).  698 
Along the years, aiming to easily ascertain the quality and level of expression of target 699 
MP, methodologies resorting to GFP fusions have been reported. Particularly, the expression of 700 
GFP fused to the termini of MP have been applied to directly monitor in whole cells for their 701 
subcellular locations by fluorescence microscopy (Goehring et al 2014). A slightly different 702 
approach was reported by Mancia et al (2004), where the production of the target MP and GFP 703 
is based on a bicistronic mRNA, thus leading to the production of two separate proteins wherein 704 
the high-yielding clones are selected based on a fluorescence-activated cell sorting procedure. 705 
Given the relevance of MP as drug targets for a variety of human diseases, advances in 706 
mammalian cell-based systems have allowed performing functional studies that otherwise could 707 
be highly hampered. Baculovirus mediated gene transduction of mammalian cells (BacMam) 708 
has been widely used due to its compatibility with a variety of mammalian cell lines and the 709 
possibility of co-infecting with multiple BacMam viruses to express protein complexes (Lyons 710 
et al 2014). Shukla et al (2012) exploited this strategy towards the development of a transient 711 
expression system for co-expression of two drug transporters (ABCB1 – P-glycoprotein – and 712 
ABCG2) in mammalian cells, which is useful to determine their contribution to the transport of 713 
a common anticancer drug substrate. Moreover, both transporters were functionally active when 714 
co-expressed (Shuka et al 2012). A distinct approach involves the codon-optimization of the 715 
sequence of the human sodium/iodide symporter (NIS) based on the highest usage frequencies 716 
in humans, while RNA instability motifs, very high (>80%) or very low (<30%) GC content 717 
regions and cis-acting motifs were also removed (Kim et al 2015). As a result, the CAI was 718 
highly improved (0.79 vs 0.97 for wild-type and optimized sequences) and from transfected 719 
cancer cells, it was found that the levels of NIS were enhanced as well as the radioiodine 720 
uptake. These results show the importance of codon usage optimizations in the development of 721 
more efficient reporters and efficient therapeutic genes, distinct goals than improving MP 722 
heterologous expression (Kim et al 2015). 723 
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To facilitate MP production for structural analysis relies on the use of HEK293S GnTI- 724 
(lacking the gene N-acetylglucosaminyl transferase I - GnTI-) and a tetracycline-inducible 725 
promoter (Chaudhary et al 2012). If on one hand, the lack of GnTI restricts N-linked glycans to 726 
a homogeneous Man5-GlcNac2, since N-linked glycosylation is often regarded as a barrier 727 
toward structure determination via X-ray crystallography due to the heterogeneity and 728 
conformational flexibility of these glycans, the inducible promoter allows the establishment of 729 
high-density cell cultures which are not always achieved if the target protein tends to be 730 
cytotoxic (Chaudhary et al 2012). Alternative approaches have been suggested to overcome 731 
toxicity issues associated with MP overexpression. Ohsfelt et al (2012) designed an anti-732 
apoptosis strategy involving co-expression of Bcl-xL gene (encodes for an anti-apoptotic 733 
protein) aiming to prevent cell death by bioreactor stresses, nutrient depletion, toxin 734 
accumulation, and stresses due to folding and processing requirements for complex proteins 735 
such as MP. The authors observed that cell death are diminished due to the co-expression of the 736 
anti-apoptotic gene and transient production of two different receptors were improved (Ohsfeldt 737 
et al 2012).  738 
 739 
1.3. Protein Quality Control: 740 
 The purity and integrity of purified protein samples are usually evaluated by 741 
electrophoresis (native or denaturant) coupled with detection methods with varying sensitivities 742 
(Oliveira and Domingues et al 2018; Raynal et al 2014). On the other hand, isoelectric focusing 743 
and capillary electrophoresis have also been used to distinguish the protein of interest from 744 
closely related undesired subproducts or contaminants (Raynal et al 2014), while UV-Visible 745 
spectroscopy is useful to detect nucleic acid contamination (Oliveira and Domingues et al 746 
2018).  747 
Mass spectrometry (MS) has been widely applied to measure molecular weights of 748 
proteins while allowing protein identification by peptide mass fingerprinting (PMF) and based 749 
on MS/MS spectra (Zhang et al 2010). By detecting mass changes introduced by post-750 
translational modifications, MS can also be used analyze these modifications (Zhang et al 751 
2010). MS-compatible detection methods enable MS analysis after electrophoresis (Raynal et al 752 
2014). Despite such analysis are usually performed after purification, Gan et al (2017) reported 753 
a native MS approach that allows the characterization of overexpressed recombinant proteins 754 
directly in crude E. coli lysates, allowing obtaining information on its identity, solubility, 755 
oligomeric state, overall structure and stability without purification. Cells were lysed in a buffer 756 
supplemented with 1M ammonium acetate to ensure compatibility with MS. Spectra were 757 
acquired for distinct proteins with molecular weights ranging from 19 to 47 kDa, and revealed 758 
highly resolved peaks, narrow charge state distributions and the anticipated stoichiometry, 759 
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thereby confirming that at least for these proteins, purification is not a prerequisite (Gan et al 760 
2017). 761 
In addition to the integrity and purity of the protein sample, homogeneity is also crucial 762 
to infer on the correct oligomeric structure of the protein. Dynamic light scattering (DLS) and 763 
more accurately analytical size exclusion chromatography (SEC) are useful to these 764 
determinations (Oliveira and Domingues et al 2018; Raynal et al 2014). In quality control 765 
methodologies, studying the secondary and tertiary structure of proteins is important to infer 766 
about their folding and monitor protein conformational changes. A range of spectroscopic 767 
techniques have been developed for such task, being circular dichroism particularly useful to 768 
determine the secondary structures and folding properties of recombinant proteins (Oliveira and 769 
Domingues et al 2018). Based on several generic or protein-specific functional assays which 770 
depend upon catalytic and binding properties of the protein of interest, it is also important to 771 
determine the activity of the target protein samples (Raynal et al 2014). Additional details of 772 
distinct analytical methods used for the characterization of therapeutic proteins including 773 
advantages and drawbacks as well as the type of information delivered from each technique can 774 
be found in the recent review by Fuh et al (2016).  775 
 776 
1.4. Insights for better decision-making processes in the upstream stage of 777 
membrane proteins: 778 
In this review, we addressed the first stage and, more specifically their (bio)synthesis by 779 
recombinant production processes. E. coli, P. pastoris and mammalian cell lines were selected, 780 
given their wide applicability and to cover hosts with different inherent complexities. Based on 781 
the information here reviewed, general insights to understand which host may better fit in a 782 
specific project are presented in the next paragraphs and summarized in Table 2 and Figure 2. E. 783 
coli is probably the better characterized host for which there are many genetic tools available. It 784 
is more suitable for low molecular weight MP and is capable to grow easily to high-cell 785 
densities at a relatively low cost. Unlike E. coli, and mammalian cell lines allow the production 786 
of larger MP and protein complexes with proper PTM including glycosylation patterns, 787 
although in this regard the performance of mammalian cell lines is best. However, obtaining 788 
recombinant proteins which better resemble their native counterparts comes with a cost and 789 
these systems are more technically challenging and this process can be lengthy. The 790 
methylotrophic P. pastoris gathers characteristics from both prokaryotic and the other higher 791 
eukaryotic hosts. Particularly, direct and indirect evidences point out the importance of P. 792 
pastoris host membranes wherein the type of lipids can influence the expression yields and 793 
overall folding of heterologous human MP while inducing membrane proliferation (HAC1 794 
overexpression and possibly the use of DMSO as an additive in culture media). The 795 
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identification of genes limiting MP overexpression resorting systems biology approaches based 796 
on -omics approaches may present additional contributions to improve recombinant MP 797 
production processes in P. pastoris. 798 
Aiming to overcome the cellular burden caused by MP overexpression, researchers have 799 
been driving their efforts towards the isolation and/or engineering of host cells, which have 800 
proven to be efficient in many cases. In addition, codon usage optimizations have been shown to 801 
be an effective strategy towards the improvement of MP expression but researchers should be 802 
aware that synonymous mutations can affect protein function. The application of fusion partners 803 
is helpful to increase MP solubility or to easily detect their expression levels and the advent of 804 
transcriptional fusions show that particularly for solubility-enhancing tags, it seems that a 805 
physical linkage between target MP and fusion may not be necessary for the desired effect, thus 806 
simplifying the overall process. 807 
Overall, the increasing understanding of MP biogenesis and the host physiological 808 
response to MP recombinant production has allowed important advances in this field. However, 809 
while it remains difficult to set general rules for a successful MP production process, the 810 
information gathered in this review can help researchers with their own MP targets. 811 
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Tables:  
Table 1 - Major advantages, limitations and general characteristics of recombinant membrane protein expression systems. 
Host Advantages Drawbacks Other characteristics References 
Escherichia coli 
Gram-negative bacterium 
Inexpensive; Rapid generation of expression 
plasmids; Fast growth; Easy scale up; Simple 
culture requirements. 
Endotoxin; Inclusion body formation; Inefficient 
protein secretion; Many MP do not fold properly; 
Lack of efficient PTM; Unable to efficiently 
express proteins larger than 120 kDa. 
Specific strains (e.g. Lemo21) or introduction of solubility tags 
may improve MP expression. Inner membrane and the inner leaflet 
of the outer membrane are mainly composed by 
phosphatidylethanolamine followed by phosphatidylglycerol and 
few cardiolipin and the outer leaflet of the outer membrane is 
highly enriched in Lipopolysaccharide. 
(Bernaudat et al 2011; 
Midgett et al 2007;  
McMorran et al 2014;  
Fernández and Vega, 2016) 
Pichia pastoris 
Methylotrophic yeast; GRAS 
organism 
Efficient protein secretion with low levels of 
endogenous proteins. Capable of performing 
many PTM; Low cost of culture media; 
Industry-scale fermentation. 
Glycosylation pattern different from mammalian; 
Intracellular recovery of large amount of cells 
may require specific equipment (French-press); 
High oxygen demand. 
Improved glyco-engineered strains obtained using the 
GlycoSwitch® technology; Wide range of genetic tools, plasmids, 
strains and promoters available; The preference for the respiratory 
growth allow to be cultivated at high cell densities. Plasma 
membrane composed of phospholipids, sterols (ergosterol) and 
sphingolipids (inositol). 
(Gonçalves et al 2013;  
Laukens et al 2015;  
Marredy et al 2011;  
Pedro et al 2015) 
Insect cells 
Baculovirus-infected cells 
More native environment than yeast; More 
compatible with eukaryotic MP because of 
similar codon usage rules than E. coli or P. 
pastoris; Well-established protocols; Good 
secretion. 
Cost; Non-native glycosylation and lipid 
environment; Cell lysis; Some of the PTM are 
not identical to those found in mammalian; Long 
production time; Relative high media costs. 
Used for MP expression as a compromise between bacterial and 
mammalian systems. Viral infection promote cell lysis and may 
lead to proteolysis of target protein. 
(Bernaudat et al 2013;  
Midgett et al 2007) 
Mammalian cells 
Stable integration and transient 
transfection 
Proper folding; Stable/transient folding;Native 
lipid environment and post-translational 
pathways. 
High media costs; Slow growth rates; Low 
expression; Viral infection; Cost; Higher 
technical requirements. 
For particular targets, may be the only expression system able to 
express a given MP in a functional and properly folded state. 
Cholesterol present in membranes may be essential for the 
functionality of certain MP. 
(Midgett et al 2007;  
Andréll et al 2013) 
Cell-Free expression 
Short time reaction; Manipulation of reaction 
conditions allow to control conveniently the 
PTM; Plasmid or DNA can be directly used for 
protein expression; Special proteins can be 
expressed with a composition of non-natural 
amino acids. 
High costs, Low protein production rates; 
Insufficiency of PTM is a bottleneck to obtain 
complex proteins in a functional form. 
May be based in prokaryotic or eukaryotic CF systems; MP may 
be produced co-translationally in artificial membrane 
environments. 
(Rajesh et al 2011;  
Proverbio et al 2013;  
Zheng et al 2014) 
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Table 2 – Critical assessment of major parameters affecting the upstream stage of recombinant MP structural biology projects for a good decision-making process. 
Parameter Escherichia coli Pichia pastoris 
Mammalian cell lines 
Baculovirus-infected Insect 
cells 
Transiently 
transfected 
Stable clones 
Gene Dosage 
Preference: Plasmid-based 
system with medium – high 
PCN 
Mixed results, screening is advisable; 
higher gene dosage can increase yield 
                  Usually favored by high gene dosage MOI affects expression yields 
Codon optimization Advisable testing for heterologous targets; “harmonized” codons often leads to outstanding improvements 
Cost Very low                       Low Very high       High 
Ease of manipulation/Labor intensive High/Low                    High/Low Low/High Low/Very High        Low/High 
Scalability Very Good                   Very Good                               Moderate        Moderate 
Timescale Days                       Week Days/Week Lengthy (Months)        Weeks 
Membrane 
Protein features 
Glycosylation Low/Absent                       High1                               Very High              High 
Other PTM Bad                       Good             Very Good                  Good 
Lipid composition Bad                    Good2                                                              Very Good                                   Good 
Specific organelles 
requirements (e.g. 
mitochondria) 
Bad                Bad                                                            Good                          Good 
Molecular Weight Limited               Good                                                           Good                                               Good 
Protein productivity Good                  Very Good                                                          Bad                       Bad 
Observations 
The source from which more 
MP structures were solved3 
Viable alternative to mammalian and 
insect cells for obtaining low cost and 
high yield of MP 
The most complete for human MP expression, 
greatly exemplified by SERT4 
Applied as a compromise between bacteria 
and mammalian cell lines 
Legend: − 1Using the GlycoSwitch® technology (Laukens et al 2015); 2Humanized pathway (Hirz et al 2013); 3Pandey et al 2016; 4Andréll et al 2013. 
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Figures: 
 
Figure 1 – Overview of the topics included in this review amenable to optimization and, thus, relevant for 
obtaining a successful strategy for recombinant MP biosynthesis. 
 
 
Figure 2 – Schematic diagram of MP structure determination pipeline focusing relevant parameters to 
optimize their upstream stage and techniques used to protein quality control. 
